ARTICLE | Company News
Gilead, GlaxoSmithKline deal
January 22, 2001 8:00 AM UTC
GSK returned to GILD development and marketing rights to GILD's NX 211 liposomal lurtotecan in order to obtain FTC clearance for GSK's recently completed merger (see BioCentury, Dec. 18, 2000). GILD h...